

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham
Vice President for Research

June 2021

Attachment A

Project #1

Subcontract between the University and Amphionic LLC Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
Title: Lightweight and Compact Radiation Shielding Enabled by Metallic Nanostructured Composites	U-M Project ID: 21-PAF06833
Direct Sponsor: Amphionic LLC	Prime Sponsor: Department of Energy Intermediate Sponsor: Fluor Marine Propulsion, LLC
Principal Investigator/Department: Mark Hammig, Nuclear Engineering & Radiological Sciences	
Project Duration: Eighteen (18) Months	Funding Support: \$211,034
Purpose: The purpose of this project is to assess shielding characteristics of the proposed metallic nanostructured composites. In particular, the performance over a range of energies, particle sizes, and nanoparticle material types are of interest.	
<u>University Employee; University Title; Relationship with Amphionic LLC</u> <ul style="list-style-type: none">● Mark Hammig; Professor, Nuclear Engineering & Radiological Sciences; Partial Owner● Suneel Joglekar; Research Fellow, Nuclear Engineering & Radiological Sciences; CEO	

Project #2

SBIR Phase I Subcontract between the University and Amphionic LLC Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
Title: Transparent, lightweight aluminum-polymer composites for sample-return missions	U-M Project ID: 21-PAF06835
Direct Sponsor: Amphionic LLC	Prime Sponsor: National Aeronautics and Space Administration
Principal Investigator/Department: Mark Hammig, Nuclear Engineering & Radiological Sciences	
Project Duration: Six (6) Months	Funding Support: \$29,526
Purpose: The purpose of this project is to develop radiation-imaging instruments, semiconductor-based charge-transit optimization, and a position-sensitive semiconductor detector.	
<u>University Employee; University Title; Relationship with Amphionic LLC</u> <ul style="list-style-type: none">● Mark Hammig; Professor, Nuclear Engineering & Radiological Sciences; Partial Owner● Suneel Joglekar; Research Fellow, Nuclear Engineering & Radiological Sciences; CEO	

Project #3

**Amendment to Research Agreement between the University and Beijing Zenithnano Technology Co., Ltd.
Reviewed by the UMOR Conflict of Interest Review Committee**

Project Information

Title: New applications of metal transparent conductor in HJT solar cell and flexible OLEDs

U-M Project ID: 21-PAF08147

Direct Sponsor: Beijing Zenithnano Technology Co., Ltd.

Principal Investigator/Department: L. Jay Guo, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS-ECE) Division

Agreement Originally Approved by the Regents: May 21, 2020

Current Project Duration: Fourteen (14) months
Additional Time: One (1) year

Current Funding Support: \$144,132
Additional Funding Support: \$134,976

Purpose: The purpose of this amendment to add additional funds and time so that Dr. Guo and a student may investigate two new applications of the ultra-thin Ag based transparent conductors.

University Employee; University Title; Relationship with Beijing Zenithnano Technology Co., Ltd.

- L. Jay Guo; Professor, EECS-ECE Division; Partial Owner

Project #4

**Phase III Subcontract Agreement between the University and Loxo Oncology, Inc. (acquired by Eli Lilly and Company)
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

U-M Project ID: 21-PAF07307

Direct Sponsor: IQVIA RDS Inc.

Prime Sponsor: Loxo Oncology, Inc.

Principal Investigator/Department: Tycel Phillips, Internal Medicine – Hematology/Oncology

Project Duration: Three (3) Years

Funding Support: \$594,266

Purpose: The purpose of this project is to compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL).

University Employee; University Title; Relationship with Eli Lilly and Company

- Marschall Runge; Executive Vice President for Medical Affairs, Dean of the Medical School; Board of Directors Member

Project #5

Amendment to Research Agreement between the University and Ningbo Inlight Technology Co., Ltd. Reviewed by the UMOR Conflict of Interest Review Committee

Project Information

Title: Extending structural colors: from very soft to very hard materials

U-M Project ID: 21-PAF08000

Direct Sponsor: Ningbo Inlight Technology Co., Ltd.

Principal Investigator/Department: L. Jay Guo, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS-ECE) Division

Agreement Originally Approved by the Regents: September 17, 2020

Project Duration: One (1) Year

Additional Time: Twenty-two (22) Months

Current Funding Support: \$132,743

Additional Support: \$250,000

Purpose: The purpose of this amendment to add additional funds and time so that Dr. Guo and a student can develop novel approaches to the design and fabrication of synthetic or structural colors, and to collaborate with Inlight engineers on applying the resulting colored pigments in coating and ceramic glaze making.

University Employee; University Title; Relationship with Ningbo Inlight Technology Co., Ltd.

- L. Jay Guo; Professor, EECS-ECE Division; Partial Owner

Project #6

Third Amendment to Research Agreement between the University and Sarcoma Alliance for Research through Collaboration Reviewed by the Medical School Conflict of Interest Board

Project Information

Title: Leiomyosarcoma (LMS): New Targets, New Therapies, New Models

U-M Project ID: 21-PAF07610

Direct Sponsor: Sarcoma Alliance for Research through Collaboration (SARC)

Principal Investigator/Department: Laurence Baker, Internal Medicine-Hematology/Oncology

Agreement Originally Approved by the Regents: December 6, 2018

First Amendment Approved by the Regents: December 3, 2020

Second Amendment Approved by the Regents: February 18, 2021

Project Duration: Three (3) years

Additional Time: N/A

Current Funding Support: \$368,598

Additional Support: \$63,525

Purpose: The purpose of this amendment is to add additional funds for the continued support of Dr. Baker's efforts related to strategic LMS vulnerabilities.

University Employee; University Title; Relationship with SARC

- Denise Reinke; Nurse Practitioner, UMH Cancer Center; President and Chief Executive Officer